Table 2 Efficacy outcomes in the... | American Society of Hematology

Table 2

Efficacy outcomes in the per-protocol population, n = 449

	Rivaroxaban			LMWH/VKA n = 101
	20 mg, n = 115	30 mg, n = 112	40 mg, n = 121	LMWH/VKA n = 101
Primary efficacy outcome
n (%)	7 (6.1)	6 (5.4)	8 (6.6)	10 (9.9)
95% CI*	2.5%-12.1%	2.0%-11.3%	2.9%-12.6%	4.9-17.5%
Symptomatic events, n (%)	3 (2.6)	4 (3.6)	2 (1.7)	7 (6.9)
Death (VTE-related)	0 (0.0)	2 (1.8)	1 (0.8)	0 (0.0)
PE, nonfatal	1 (0.9)	1 (0.9)	0 (0.0)	1 (1.0)
Recurrent DVT	2 (1.7)	1 (0.9)	1 (0.8)	7 (6.9)†
Asymptomatic deterioration on ultrasound and/or perfusion lung scanning, n (%)	4 (3.5)	2 (1.8)	6 (5.0)	3 (3.0)

	Rivaroxaban			LMWH/VKA n = 101
	20 mg, n = 115	30 mg, n = 112	40 mg, n = 121	LMWH/VKA n = 101
Primary efficacy outcome
n (%)	7 (6.1)	6 (5.4)	8 (6.6)	10 (9.9)
95% CI*	2.5%-12.1%	2.0%-11.3%	2.9%-12.6%	4.9-17.5%
Symptomatic events, n (%)	3 (2.6)	4 (3.6)	2 (1.7)	7 (6.9)
Death (VTE-related)	0 (0.0)	2 (1.8)	1 (0.8)	0 (0.0)
PE, nonfatal	1 (0.9)	1 (0.9)	0 (0.0)	1 (1.0)
Recurrent DVT	2 (1.7)	1 (0.9)	1 (0.8)	7 (6.9)†
Asymptomatic deterioration on ultrasound and/or perfusion lung scanning, n (%)	4 (3.5)	2 (1.8)	6 (5.0)	3 (3.0)

CI indicates confidence interval; DVT, deep vein thrombosis; PE, pulmonary embolism; and VTE, venous thromboembolism.

Two-sided 95% confidence intervals are presented.

One patient presented with both DVT and PE.